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Abstract
The maintenance of magnesium (Mg2+) homeostasis is essential for human life. The
Cystathionine-β-synthase (CBS)-pair domain divalent metal cation transport mediators
(CNNMs) have been described to be involved in maintaining Mg2+ homeostasis. Among
these CNNMs, CNNM2 is expressed in the basolateral membrane of the kidney tubules
where it is involved in Mg2+ reabsorption. A total of four patients, two of them with a sus-
pected disorder of calcium metabolism, and two patients with a clinical diagnosis of primary
tubulopathy were screened for mutations by Next-Generation Sequencing (NGS). We found
one novel likely pathogenic variant in the heterozygous state (c.2384C>A; p.(Ser795*)) in
the CNNM2 gene in a family with a suspected disorder of calcium metabolism. In this family,
hypomagnesemia was indirectly discovered. Moreover, we observed three novel variants of
uncertain significance in heterozygous state in the other three patients (c.557G>C; p.
(Ser186Thr), c.778A>T; p.(Ile260Phe), and c.1003G>A; p.(Asp335Asn)). Our study shows
the utility of Next-Generation Sequencing in unravelling the genetic origin of rare diseases.
In clinical practice, serum Mg2+ should be determined in calcium and PTH-related
disorders.
Introduction
Magnesium (Mg2+) is an essential ion for human life that is known to play a central role in the
regulation of numerous cellular functions [1]. Thus, most enzymes depend on Mg2+ as either
an activator or a cofactor [2, 3]. Moreover, Mg2+ has anti-inflammatory properties and acts as
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calcium antagonist within cells [4]. Furthermore, Mg2+ is critical for mitochondria to carry
out oxidative phosphorylation, as well as for cell proliferation, cell signaling and nucleotide
binding [5]. Therefore, the maintenance of Mg2+ homeostasis is essential.
Mg2+ is the second most abundant intracellular cation [more or less 24–73 mg/dL] only
surpassed by calcium. Only 1% of the body’s Mg2+ is found in the blood [1.7–2.5 mg/dL] [1].
The Cystathionine-β-synthase (CBS)-pair domain divalent metal cation transport mediators
(CNNMs) have been described to be involved in maintaining Mg2+ homeostasis. This family
includes four proteins (CNNM1, CNNM2, CNNM3 and CNNM4) [6]. Among these, the
CNNM2 protein, that was described in 2003 [7], is ubiquitously expressed, although mostly at
the basolateral membrane in both the thick ascending limb of the Henle’s loop, and the distal
collecting tubule within the kidney where it is involved in Mg2+ reabsorption [8]. It is also
expressed abundantly in brain, lung, spleen, testis, liver and heart [9]. The exact mechanism by
which these proteins facilitate the passing of Mg2+ through the cell membranes has been
widely discussed [10, 11]. These proteins could be themselves Mg2+ transporters [6, 10] or reg-
ulate other proteins that transport Mg2+ [11].
The CNNM2 protein (UniProtKB: Q9H8M5) structurally contains an N-terminal extracel-
lular domain (1–250 amino acids) with a large signal peptide (64 amino acids) and one glyco-
sylation site (asparagine residue N112) [12]; a transmembrane domain (the so-called “domain
of unknown function 21” or DUF21) with four predicted transmembrane α-helices (251–431
amino acids); and a cytosolic region with two important domains: the CBS-par domain (Bate-
man domain) (429–578 amino acids) and the cyclic nucleotide-binding homology domain
(CNBH) (621–824 amino acids) [12]. CBS-par domains dimerize in a head-to-head manner
forming disc-like structures that enclose central nucleotide-binding sites for Mg2+-ATP
(Adenosine triphosphate). Dimerization depends on Mg2+-ATP binding and is enhanced by
phosphatases of regenerating liver (PRL) binding [13]. PRL binding is mediated by a loop
from CBS-pair domain that extends into the phosphatase active site [6]. The CNBH domain
does not bind cyclic nucleotides. They form dimers in solution as well. CNBH mediates CBS-
par domains dimerization and is required for the Mg2+ efflux activity [14]. It has been pro-
posed that the CNNM protein activity is regulated by conformational changes in the CBS-pair
domain associated with Mg2+-ATP binding [6].
The CNNM2 protein is encoded by the CNNM2 gene (MIM 607803) which was mapped to
chromosome 10q24.32 [15]. It has eight exons that encode a deduced 875-amino acid protein.
Mutations in this gene are associated with dominant renal hypomagnesemia (MIM 613882)
and with hypomagnesemia, seizures, and mental retardation (MIM 616418). So far, according
to the Human Gene Mutation Database, 6 pathogenic variants in the CNNM2 gene associated
with hypomagnesemia or with hypomagnesemia, seizures, and mental retardation have been
described (Table 1 and Fig 1).
In the present study, we report a novel likely pathogenic variant in the CNNM2 gene in a
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Population
Four patients, two of them with a suspected disorder of calcium metabolism (CA106 and
SOR171), and two patients with a clinical diagnosis of primary tubulopathy (SOR79 and
SOR204) were referred to our hospital for genetic testing. A total of 44 genes whose mutations





Exon Domain Phenotype Variant
Class
Reference
c.117delG p.(Ile40Serfs�15) 1 Extracellular Hypomagnesemia DM Stuiver M et al [8]
c.154C>T p.Leu52Phe 1 Extracellular Epilepsy and autism spectrum disorder VOUS Long S et al [16]
c.364G>A† p.Glu122Lys† 1 Extracellular Mental retardation, seizures and
hypomagnesemia
DM Arjona FJ et al [17]
c.806C>G p.Ser269Trp 1 DUF21 Mental retardation, seizures and
hypomagnesemia
DM Arjona FJ et al [17]
c.988C>T p.Leu330Phe 1 DUF21 Mental retardation, seizures and
hypomagnesemia
VOUS Arjona FJ et al [17]
c.1069G>A p.Glu357Lys 1 DUF21 Mental retardation, seizures and
hypomagnesemia
DM Arjona FJ et al [17]
c.1642G>A† p.Val548Met† 2 Bateman Hypomagnesaemia and epileptic
encephalopathy
DM Accogli A et al [18]
c.1703C>T p.Thr568Ile 2 Bateman Hypomagnesemia DM Stuiver M et al [8]
c.2291G>A p.Arg764Gln 7 CNBH Autism spectrum disorder Intellectual disability,
seizures and epilepsy
VOUS Kosmicki JA et al [19], Snoeijen-
Schouwenaars FM et al [20]
� Numbering is according to DNA sequence (Ensembl: ENST00000369878.9)
† in homozygous; VOUS, variant of uncertain significance; DM, Disease causing mutation
https://doi.org/10.1371/journal.pone.0239965.t001
Fig 1. Schematic representation of CNNM2 protein at the plasma membrane, representing the position of
thirteen variants. Variants marked in bold have not been reported to date. The CNNM2 protein structurally contains
an N-terminal extracellular domain with one glycosylation site (asparagine residue N112); a transmembrane domain
(“domain of unknown function 21” or DUF21) with four predicted transmembrane α-helices (TM1-4); and a cytosolic
region with two domains: the CBS-par domain (Bateman domain) and the cyclic nucleotide-binding homology
domain (CNBH).
https://doi.org/10.1371/journal.pone.0239965.g001
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are a recognized cause of primary tubulopathies were tested by a Next-Generation Sequencing
(NGS) panel: patient CA106 presented with elevated calcium (Ca2+) and parathyroid hor-
mone (PTH) levels and hypocalciuria; patient SOR171 presented with secondary hyperpara-
thyroidism and nephrocalcinosis. On the other hand, SOR79 and SOR204 presented with
hypokalemic metabolic alkalosis and were clinically diagnosed of Bartter syndrome (BS). Clin-
ical diagnoses were made by adult and pediatric endocrinologists or nephrologists. In all cases,
the molecular analysis was done in the Molecular Genetic Laboratory at Biocruces Bizkaia
Health Research Institute, Barakaldo, Spain.
Next-generation sequencing
Extraction and purification of genomic DNA from peripheral blood leukocytes were per-
formed according to the manufacturer’s instructions (MagPurix Blood DNA Extraction Kit
200. Zinexts Life Science Corp). DNA purity and concentration were determined using Qubit
2.0 fluorometer (Thermo Fisher Scientific).
One customized gene panel with 44 genes of interest and their untranslated UTR regulatory
regions was designed using the computer tool Ion AmpliSeq Designer (Ion Torrent Life Tech-
nologies). The panel is covered by 1153 amplicons, with an expected coverage of 98% and con-
tained 44 genes whose mutations are associated with different tubulopathies (SLC12A1,
KCNJ1, BSND, CLCNKB, CLCNKA, CASR, MAGED2, KCNJ10, SLC12A3, SCNN1B, SCNN1G,
SCN4A, SCNN1A, NR3C2, WNK4, WNK1, CUL3, KLHL3, ATP6V1B1, CA2, SLC4A4, SLC4A1,
ATP6V0A4, AVPR2, AQP2, CLCN5, OCRL1, HNF1B, KCNA1, CLDN16, CLDN19, TRPM6,
FXYD2, EGF, CNNM2, DMP1, FGF23, SLC34A3, PHEX, SLC34A1, SLC9A3R1, ENPP1,
GNA11, AP2S1). Libraries were prepared according to the manufacturer’s instructions (Ion
AmpliSeq Library Kit 2.0). The resulting DNA libraries were ready for downstream template
preparation using the Ion OneTouch™ 2 System followed by sequencing by the Ion PGM Hi-Q
sequencer (Thermo Fisher Scientific). Torrent SuiteTM Software (Life Technologies, Foster
City, CA, USA) was used for alignment to the human reference genome (hg19/GRCh37), and
variant calling. Variants were filtered to include only those with a p-value < 0.001, and a
Minor Allele Frequency (MAF) <1% in 1000 genomes browser, Exome Aggregation Consor-
tium (ExAC) and ESP Exome Variant Server (ESP) and analyzed on the Ion ReporterTM Soft-
ware version 5.2 (Life Technologies, Foster City, CA, USA). Not appropriately covered
amplicons (<20x fold) and candidate variants were assessed by Sanger sequencing.
Variants were named according to the Human Genome Variation Society guidelines, and
then classified following the American College of Medical Genetics (ACMG) guidelines [21].
Results
Patients
Patient CA106 is a 39-year-old male who was referred for evaluation of elevated serum Ca2
+ and PTH levels in several routine blood laboratory analyses and hypocalciuria. Laboratory
results showed serum Ca2+ of 10.2 to 10.8 mg/dL (reference range 8.5–10.4) and high intact
PTH levels (93–128 pg/mL, reference range 10–65), whereas serum phosphate (3.5 mg/dL, ref-
erence range 2.6–4.8) and 25-hydroxyvitamin D levels (39 ng/mL, reference range 9–47) were
within the normal range. He was clinically diagnosed of Familial hypocalciuric hypercalcemia,
therefore the CASR (MIM 601199), AP2S1 (MIM 602242) and GNA11 (MIM 139313) genes
were requested for genetics analysis. Furthermore, patient CA106 had a personal history of idi-
opathic panhypopituitarism on substitutive hormonal treatment except growth hormone, skin
sarcoma (dermatofibrosarcoma protuberans), high blood pressure, basilar artery fenestration,
and he had a sprain in the wrist and back pain. We did not find alterations in the proposed
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genes by NGS, but we found a novel likely pathogenic variant in the heterozygous state in the
CNNM2 gene. Therefore, a new laboratory evaluation was requested confirming the previous
results and the presence of moderate hypomagnesemia (1.38 mg/dL, reference range 1.7–2.5).
Furthermore, hypomagnesemia was observed within his family as well (sister and mother
showed hypomagnesemia, 1.32 mg/dL and 1.42 mg/dL respectively). Both had the variant car-
ried by CA106.
Patient SOR171 is a 17-year-old male who was referred for evaluation of elevated serum
PTH levels, low 25-hydroxyvitamin D levels, hypocalciuria, testicular microlithiasis and
nephrocalcinosis. He was treated with 25-hydroxyvitamin D. Laboratory evaluation after
25-hydroxyvitamin D treatment showed normal serum calcium (9.2 mg/dL, reference range
8.5–10.4), high intact PTH (91.2 pg/mL, reference range 10–65), normal serum phosphate (3.7
mg/dL, reference range 2.6–4.8), serum magnesium levels at the lower limit of the normal
ranges (1.7 mg/dL, reference range 1.7–2.5) and 25-hydroxyvitamin D levels of 18.5 ng/mL
(reference range 9–47). A variant of uncertain significance in the CNNM2 gene in the hetero-
zygosis state was identified. Later, using a NGS panel of genes associated with phosphate and
calcium metabolism showed a described variant of uncertain significance (c. 1039G>A; p.
Val347Ile) in the heterozygosis state in the VDR gene (mutations in the VDR gene are associ-
ated with vitamin D-resistant rickets type IIA, OMIM �601769).
Furthermore, we identified variants of uncertain significance in the CNNM2 gene in two
patients previously diagnosed of Bartter syndrome. This syndrome is a heterogenic autosomal
recessive disorder of the salt reabsorption at the thick ascending limb of Henle´s loop. BS is
characterized by hypokalemia, metabolic alkalosis, hyperaldosteronism with normal or low
blood pressure, renal salt loss and hyperplasia of juxtaglomerular apparatus [22]. In brief,
patient SOR79 is a 3-month-old female with polyuria, polydipsia, vomiting, constipation, salt
craving, dehydration, and failure to thrive. A history of hydramnios was also recorded. Charac-
teristically, she had hypokalemia (serum K+ 3 mEq/l), hypochloremia (serum Cl- 86 mEq/l),
metabolic alkalosis (serum pH 7.46, bicarbonate 29 mEq/l), and nephrocalcinosis. Moreover,
increased plasma renin activity (500 ng/ml/h), and aldosterone levels (2008 pg/ml) were
observed. At the time of the study, she had elevated serum magnesium levels (2.7 mg/dL, refer-
ence range 1.7–2.5). We identified two likely pathogenic nonsense variants in compound het-
erozygous state (p.[(Gln75�)];[Arg761�]) in the SLC12A1 gene (Na-K-2Cl cotransporter
NKCC2, pathogenic mutations cause type I BS (OMIM #601678)) confirming a clinical diag-
nosed of neonatal Bartter syndrome type 1. The second patient, SOR204, is a premature who
was referred for evaluation of vomiting and hypotonia. Characteristically, he had hypokalemia
(serum K+ 2.3–2.8 mEq/l), hypochloremia (serum Cl- 96–78 mEq/l), metabolic alkalosis
(serum pH 7.52–7.59, bicarbonate 27.9–35.9 mEq/l), and nephrocalcinosis. At the time of the
study, he had low serum magnesium levels (1.51 mg/dL, reference range 1.7–2.5). Moreover,
patient SOR204 had Down syndrome and showed a delay in psychomotor development. In
this patient two likely pathogenic variants in compound heterozygous state (p.[(?)];
[(Glu490Lys)]) in the CLCNKB gene (Chloride Channel Protein ClC-Kb, pathogenic muta-
tions cause type III BS, OMIM #607364) were identified confirming a clinical diagnosed of
Bartter syndrome type 3.
Regarding molecular diagnosis, we observed 4 novel variants in the CNNM2 gene. One
likely pathogenic variant (c.2384C>A; p.(Ser795�)) in patient CA106 and three variants of
uncertain significance (c.557G>C; p.(Ser186Thr) in patient SOR79, c.778A>T; p.(Ile260Phe)
in patient SOR204, and c.1003G>A; p.(Asp335Asn) in patient SOR171), all in the heterozy-
gous state (Table 2 and Fig 1). The nonsense variant p.(Ser795�) is located in the CNBH
domain, and it was considered disease-causative since this change in the CNNM2 gene dis-
rupts the reading frame and presumably leads to a truncated protein lacking the COOH-
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terminus, thus hypothetically generating a faulty CNNM2 protein unable to perform its func-
tion (Table 2).
The missenses p.(Ser186Thr) (in the extracellular domain), p.(Ile260Phe) and p.
(Asp335Asn) located in the DUF21 domain were considered of the uncertain significance
(Table 2).
In addition, genetic testing was done to determine whether asymptomatic family members
had inherited the same variant as the index cases. Two members (mother and sister of patient
CA106) had the variant p.(Ser795�) in heterozygous state and both presented with hypomag-
nesemia, therefore, they were clinically diagnosed of dominant hypomagnesemia. The variant
p.(Asp335Asn) was not present in the remaining members of family SOR171, therefore we
considered it as de novo variant. Finally, the variant p.(Ile260Phe) in patient SOR204 was
inherited from the mother who was asymptomatic. We could not perform genetic analyses in
family SOR79.
Discussion
In this study we described 4 patients who had variants in the CNNM2 gene. The complete
genetic study revealed one likely pathogenic variant (p.(Ser795�)) in one patient with elevated
serum Ca2+ and PTH levels, hypocalciuria and hypomagnesemia; and 3 variants not previ-
ously reported of uncertain significance in other three patients diagnosed of Bartter syndrome
(p.(Ser186Thr) and p.(Ile260Phe)) and calcium metabolism disorder (p.(Asp335Asn)). In
addition, these patients diagnosed of BS had disease causing mutations in other genes
(SLC12A1 and CLCNKB, respectively). Moreover, the patient with a calcium metabolism dis-
order had a variant of uncertain significance in the VDR gene.
In accordance with previous studies of the CNNM2 gene [8, 17, 18], we found variants in
the three CNNM2 regions; the extracellular domain, the transmembrane domain and the cyto-
solic domain. So far, only 6 pathogenic variants in the CNNM2 gene have been reported.
These pathogenic variants have been associated with hypomagnesemia, seizures, and mental
retardation. Furthermore, other 3 variants of uncertain significance were described associated
with hypomagnesemia, mental retardation, seizures, epilepsy and autism [16, 17, 19].
In our cohort, two patients (CA106 and SOR171) presented with elevated serum Ca+ and
PTH levels and hypocalciuria. Initially, both were clinically suspected of a calcium metabolism
disorder and the genetic analysis was performed according to this. We did not find pathogenic
variants in the genes associated with Familiar hypocalciuric hypercalcemia (CASR, GNA11
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CA0106 M c.2384C>A p.(Ser795�) 7 CNBH - 1 (disease
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Likely Pathogenic
† Numbering is according to DNA sequence (Ensembl: ENST00000369878.9), in heterozygous.
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https://doi.org/10.1371/journal.pone.0239965.t002
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and AP2S1) by NGS. On the other hand, the genetic analysis showed a likely pathogenic vari-
ant (p.(Ser795�)) in patient CA106 and one VOUS (p.(Asp335Asn)) in patient SOR171, both
variants in the heterozygous state in the CNNM2 gene which is involved in magnesium
homeostasis. Normally, Mg2+ is not requested in a routine blood test, therefore after the dis-
covery of the variants in the CNNM2 gene (gene associated with dominant hypomagnesemia)
a new blood test was requested. The results showed that CA106 had low serum Mg2+. Genetic
analysis were performed in his mother and sister, both had the variant p.(Ser795�) in the het-
erozygous state and presented with hypomagnesemia without other remarkable symptoms.
This phenotype variability within the family has been observed previously in dominant hypo-
magnesemia due to variants in the CNNM2 gene [8]. Thus, the initial diagnosis was changed
to dominant hypomagnesemia. Regarding molecular diagnosis, the novel p.(Ser795�) variant
produces a strongly truncated protein (missing more than 10% of its amino acids), and, as far
as we know, it is the first described nonsense mutation associated with hypomagnesemia in
the CNNM2 gene. This nonsense variant is located within the CNBH domain. It was hypothe-
sized that CNBH domain dimerization plays an important role in regulating CNNM2 activity
[14]. The loss of this domain presumably results in a non-functional protein impairing Mg2
+ reabsorption in the kidney. It has been described that homozygous mutations in the
CNNM2 gene cause hypomagnesemia, epileptic encephalopathy, brain malformations and
mental retardation [18]. Nevertheless, a mild degree of intellectual disability has been
described in other patients with variants in the CNNM2 gene in the heterozygous state when
these variants affect important protein domains [17]. However, this was not the case in patient
CA106 (he worked as a computer programmer).
On the other hand, although SOR171 showed an overlapping phenotype with CA106, he
had serum magnesium levels at the lower limit of the normal ranges, testicular microlithiasis,
nephrocalcinosis and vitamin D deficiency. He had two variant of uncertain significance: one
de novo variant p.(Asp335Asn) in the CNNM2 gene and one variant in the VDR gene
(c.1039G>A; p.Val347Ile), both in the heterozygous state. The variant p.(Asp335Asn) pro-
duces a conserved amino acid change. In silico mutation analyses predict the change as non-
pathogenic. However, we hypothesize that variant p.(Asp335Asn) could have an effect on mag-
nesium homeostasis. He presented with a similar phenotype than another patient previously
described with hypocalciuria, elevated serum PTH levels and hypovitaminosis D, and normal
serum calcium levels as well [18]. On the other hand, this other patient with a similar pheno-
type presented with hypomagnesemia. Importantly, our patient also had a variant of uncertain
significance in the VDR gene in the heterozygous state. In most cases the disease associated
with this VDR gene is transmitted in an autosomal recessive manner (both alleles must be
altered) and patients present severe hypocalcemia and secondary hyperparathyroidism, with
elevated serum levels of 1,25-dihydroxyvitamin D. However, some changes in the heterozy-
gous state have also been described as disease causing [24]. Moreover, the VDR gene has been
linked to nephrocalcinosis in a prevalence study of monogenic causes in paediatric patients
with such alterations [25]. Unfortunately, one of the limits of our study was the lack of func-
tional analysis; therefore, we are unable to determine whether these changes are responsible
for the phenotype of the patient. However, we cannot rule out that the combination of the two
alterations observed will produce the phenotype observed in our patient. Importantly,
although a history of hypocalciuria was reported within the family, the parents only presented
with the variant p.Val347Ile in the VDR gene.
Furthermore, our genetic analysis showed two missenses variants that we considered
VOUS. Thus, patient SOR79 who had two pathogenic variants in compound heterozygous
state in the SLC12A1 confirming its clinical diagnosed of neonatal BS type 1, presented with
the variant p.(Ser186Thr) in the CNNM2 gene. This change is located in the CNNM2
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extracellular domain. Patient SOR79 presented with hypermagnesemia, therefore this variant
could be a benign polymorphism. On the other hand, patient SOR204 who had two variants in
a compound heterozygous state in the CLCNKB gene confirming its clinical diagnosed of BS
type 3, presented with the variant p.(Ile260Phe) in the CNNM2 gene. This change is located in
the DUF21 domain. The variant p.Ser269Trp, which is located in the same domain only 9
amino acids downstream of our variant, has been described associated to mental retardation,
seizures and hypomagnesemia in the heterozygous state. This p.Ser269Trp variant decreases
Mg2+ uptake and the expression is reduced compared with wild-type [17]. Though in silico
mutation analyses predict the change as non-pathogenic, variant p.(Ile260Phe) may cause a
similar defect in the protein. Moreover, we cannot exclude a mild effect on the phenotype
since SOR204 presented with hypomagnesemia. However, hypomagnesemia is frequent in
patients with pathogenic variants in the CLCNKB gene [26].
In conclusion, our study shows the utility of NGS and more extensive studies (whole
exome-sequencing) in unravelling the genetic origin of rare diseases. Thus, a novel likely path-
ogenic variant in the CNNM2 gene (p.(Ser795�)) has been found associated to dominant hypo-
magnesemia in a patient previously suspected of a calcium metabolism disorder. Moreover,
three VOUS in the CNNM2 gene have been found in our cohort. Among them, p.(Asp335Asn)
and p.(Ile260Phe) variants may be implicated in patient’s phenotypes. Mg2+ acts as a Ca2
+ antagonist within cells [4]. Therefore, changes in the Mg2+ availability within the cell may
cause alterations in the unbound Ca2+ fraction [1], which is an essential secondary messenger
in many cellular functions. We underline that serum Mg2+ should be determined in calcium
and PTH-related disorders in clinical practice. Understanding the functional impact of patho-
genic variants in proteins implicated in the Mg2+ homeostasis is critical for guiding pharma-
cological research, and could facilitate individualized treatment of patients in the future.
Acknowledgments
We thank patients and families and their pediatric nephrologists and endocrinologists who
collaborated with the genetic study.
Author Contributions
Conceptualization: Alejandro Garcı́a-Castaño, Leire Madariaga, Luis Castaño, Sonia
Gaztambide.
Data curation: Montserrat Antón-Gamero, Natalia Mejia, Jenny Ponce, Anı́bal Aguayo, Sonia
Gaztambide.
Formal analysis: Alejandro Garcı́a-Castaño, Sara Gómez-Conde, Gustavo Pérez de Nanclares,
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